Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 270 Results

October 9, 2023

Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

October 6, 2023

Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress

September 20, 2023

Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder

August 23, 2023

Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder

August 8, 2023

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 1, 2023

Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023

June 8, 2023

Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

June 2, 2023

Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference

May 24, 2023

Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting

May 11, 2023

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

«...5 678 9 10...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top